drug protocol number

C5351004 (GBT021601)

drug sponsor

Global Therapeutics Inc

drug study

Osivelotor

drug trial site

Prince Mohammad Bin Naser Hospital (Jazan), King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase